During intralipid (IL) infusion, premature neonates significant decreases in pO which are accompanied by pulmonary vasoconstriction. The mechanism by which intralipids induce these changes i s not yet known. This study was undertaken t o evaluate the hypothesis t h a t IL, via the provision of increased f a t t y acid precursors, a c t s by increasing biosynthesis of the vasoconstricting prostanoid, thromboxane.
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Children's Hospital, Dept. of Pediatrics, Chicago. During intralipid (IL) infusion, premature neonates significant decreases in pO which are accompanied by pulmonary vasoconstriction. The mechanism by which intralipids induce these changes i s not yet known. This study was undertaken t o evaluate the hypothesis t h a t IL, via the provision of increased f a t t y acid precursors, a c t s by increasing biosynthesis of the vasoconstricting prostanoid, thromboxane.
Thirteen neonates (<I750 grams) who had not yet been fed, and were not expected t o recelve any enteral nutrition for 5 days were randomized t o receive either TPN with IL (n=7) or TPN without IL (n=6). Plasma prostanold levels were drawn on day 1, 3 and 5 of study and r e s u l t s are a s follows: The p i g l e t is a u s e f u l pharmacodynamic model f o r t h e study of catecholamines and an a c c e p t a b l e pharmacokinetic (PK) model f o r methylxanthines. We evaluated t h e p i g l e t a s a model f o r t h e PK of c e f o n i c i d , a second generation cephalosporin.
Cefonicid (C) PK were evaluated i n 1 3 p i g l e t s a t 3 (n=6) and 6 (n=7) days of age. Following a s i n g l e I . V . dose of 50 mglkg, blood samples (n=10) were obtained over 24 h r . Serum u l t r a f i l tr a t e was prepared f o r determination of unbound C by membrane c e n t r i f u g a t i o n , and C was q u a n t i t a t e d by HPLC (LLD = 5 mg/L; C.V. <lo%). ESTRIP was used t o g e n e r a t e polyexponential parameter e s t i m a t e s necessary f o r PK c a l c u l a t i o n s . No s i g n i f i c a n t d i f f e rences were found between t h e 3 and 6 day o l d animals with r e s p e c t t o TI (1.4f0.1 vs. 1.04f0.07 h r ) , t o t a l c l e a r a n c e (CL; 0.39f0.03 vs. 0.31f0.07 Llhrlkg) o r Vd(area) (0.3t0.04 vs. 0.28t0.06 Llkg). The PK parameters f o r C i n t h e p i g l e t s were markedly d i f f e r e n t from t h o s e i n young a d u l t humans (T&=4.8 h r ; Vd=O. 12 Llkg), a s was t r u e f o r t h e f r e e f r a c t i o n of C from p i g l e t s (93.0%) v s . h e a l t h y a d u l t s (3.1%). Comparison of p i g l e t serum t o t h a t from human neonates revealed a s i g n i f i c a n t d i f f e r e n c e i n t h e albumin concentration (1.5f0.2 gm% f o r p i g l e t v s . 4.3f0.2 gmZ f o r human) and t h e t o t a l protein:albumin r a t i o (2.7f0.3 f o r p i g l e t vs. 1.5f 0.1 f o r human). The markedly increased CL of C i n t h e p i g l e t may be consequent t o i n t e r s p e c i e s d i f f e r e n c e s i n C p r o t e i n binding. Our d a t a suggest t h a t t h e p i g l e t may n o t be an adequate model t o e v a l u a t e t h e PK of C f o r e x t r a p o l a t i o n t o t h e human i n f a n t . Univ. of C a l . , I r v i n e .
PHARMACOKINETICS AND RESPIRATORY PHARMACO-DYNAMICS

Previous s t u d i e s e v a l u a t i n g aminoglycoside (A) d i s p o s i t i o n i n premature i n f a n t s have described t h e r e l a t i o n s h i p between various i n d i c e s of maturation and serum A c l e a r a n c e a s e i t h e r l i n e a r o r exponential. Pharmacokinetic s t u d i e s c a r r i e d out i n 992 i n f a n t s demonstrated a d i s t i n c t l y bi-phasic p a t t e r n when i n d i c e s of A e l i m i n a t i o n a r e compared t o i n d i c e s of maturation. G e s t a t i o n a l
age (GA) 24-39 wks, p o s t n a t a l age (PNA) 1-20 wks, postconceptiona 1 age (PCA) 25-53 wks, birthweight (BW) 380-3950 gm and study weight (SW) 350-4620 gm were recorded. S e r i a l A serum concentrat i o n s were determined by RIA. Volume of d i s t r i b u t i o n (Vd) 0.29-0.63 L/kg, e l i m i n a t i o n r a t e constant (Ke) 0.029-0.231 hr-1, and serum c l e a r a n c e (Cl) 0.0056-0.630 L/hr were c a l c u l a t e d . When Ke and C 1 were compared t o GA, PCA, B W and SW, t h e r e l a t i o n s h i p was d i s t i n c t l y bi-phasic. P r i o r t o 34 wks GA and 35 wks PCA, Ke and C 1 increased slowly with r e s p e c t t o increased GA and PCA. A f t e r 35 wks GA and 36 wks PCA, Ke and C 1 increased r a p i d l y with respect t o i n c r e a s i n g GA and PCA. These changes a t 34-36 wks may r e p r e s e n t a f u n c t i o n a l change i n t h e neonatal kidney a t t h i s s t a g e of maturation. Vd (L/KG) was found t o decrease s l i g h t l y with i nc r e a s i n g GA, PCA, B W and SW. To determine whether altered production of vasoactivc eicosanoids precedes the development of symptomatic patent ductus arteriosus (SPDA) in infants who have received prophylactic indomcthacin (I), major urinary metabolites of thromboxane, prostacyclin and PGE2 were measured by gas chromatography-mass spectrometry. The 4 infants (26-27 wks gestation; 840-870 gm birth weight), 2 of whom had SPDA on days 6 and 11 were matched for birth weight, gestational age, race, severity of hyaline membrane disease and intensity of ventilatory support. All received prophylactic I, 0.2 mg/kg 24 hr after birth. Serum I was 582-1283 mg/ml and 155-960 ng/ml 24 and 96 hrs post dosc respectively. There were no differences in urinary PG excretion patterns between infants who were protected and infants who developed SPDA, except that the symptomatic infants showed marked suppression of PC excretion when given additional I as treatment. Failure of I to protect against SPDA appears unrelated to systemic production of vasoactive PGs. Scrum levels of I did not discriminate babies likely to develop SPDA dcspitc prophylactic treatment. There appears to be no rationalc for increasing the prophylactic dose of I to afford greater protection from SPDA.
This d a t a suggests t h a t n e i t h e r a l i n e a r nor exponential model f u l l y d e s c r i b e s t h e improvement of A C 1 i n t h e neonate. A biphasic model with a breakpoint a t 34 wks G A o r 35 wks PCA appears t o be t h e most a p p r o p r i a t e d e s c r i p t i o n of t h e improvement. Therefore, G A and PCA a r e important v a r i a b l e s t o evaluate i n t h e determination of
The role of PGs in the onset of SPDA following prophylactic I rcmains to be elucidated. This work was supported by SCOR HL-14214 and AD-17413.
Hospital for Sick Children, Divisions of Neonataology and Clin. Pharmacology. Toronto. Ontario Attempts to wean ventilator-dependent infants with BPD have been made by trying to reduce bronchospasm using P agonist drugs or caffeine. However, all drugs tested to date were not P2 selective and their use has been associated with unaccepted tachycardia. We studied the pharmacokinetics and respiratory dynamics of salbutamol after an IV infusion of 1 psn(s/mn over 30 min. Our patients were 6 ventilatory dependent infants with BPD (24-28 wks gest. age; 50-90 days postnatal age). Serum concentrations were measured by a new HPLC method. Elimination TI12 of salbutamol was 133 f 27 min (mean * SEM). Calculated distribution volume was 129 f 397 mVkg and clearance rate of 7.5 i 2.6 mVkg/min. The shorter TI12 in these patients when compared to healthy adults or patients with CF may be explained by smaller Vd in the presence of comparable clearance. Passive expiratory, total respiratory system compliance (CRS) improved in all infants (mean 23O/0) though in only 516 was this an immediate effect. Airflow resistance decreased in 516 patients, (mean 23.3%). No consistent changes lasting for more than 1 hour were seen with Tc 02, Tc C02, arterial or capillary C02 or 02. All 6 infants developed tachycardia (froml58;t2/min to202 * Glmin), which peaked at the end of the infusion. There was a significant positive correlation between Vd and % change in heart rate. Traditionally, it was thought that during the postnatal period P agonists do not exert bronchodilatatory effects due to the lack of P2 receptors. The present study indicates that the emergence of these receptors stafls to take dace in the postnatal period. 
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Hematology&Oncology , Toronto, Ontario Despite significant improvement in the induction of treatment for ALL relapse rates during maintenance therapy are still relatively high. Putative mechanisms for maintenance failure include patients' compliance, pharmacokinetic variability of 6 mercapto purine (6MP) and methotrexate (MTX), as well as differences in tumor sensitivity. However, the issue of physicians' compliance with the recommended doses of chemotherapy as a factor affecting outcome has not yet been addressed. We studied the prescription patterns of maintenance therapy for children with ALL and their association with duration of complete remission. Both 6MP and MTX were prescribed in doses significantly lower than those recommended during maintenance therapy. Out of 212 evaluated patients. relapsed patients (n = 101) received significantly less MTX as compared to nonrelapsed patients (n = 111) during the first 2 years ol maintenance therapy (p-z.05).
In the group of standard risk patients who received the same induction therapy (n = 92). 11/17 (64%) of those receiving less than 50% of their recommended MTX dose relapsed, significantly more than those receiving more than 50% of the dose (28/75;37%) (p-zO.05).
It is concluded that physicians' failure to adhere to the recommended protocol is associated with a higher relapse rate of ALL. Improved physicians'compliance may improve the prognosis of this fatal disease.
